{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:28:50Z","timestamp":1791163730157,"version":"4.1.0"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006244","name":"KiKa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fonds Stimulans"},{"DOI":"10.13039\/501100001722","name":"Royal Netherlands Academy of Arts and Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001722","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Netherlands Organization for Scientific Research"}],"content-domain":{"domain":["drupjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.drup.2014.12.001","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T21:09:07Z","timestamp":1418245747000},"page":"18-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"special_numbering":"C","title":["Molecular basis of resistance to proteasome inhibitors in hematological malignancies"],"prefix":"10.1016","volume":"18","author":[{"given":"Denise","family":"Niewerth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan J.L.","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Cloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2014.12.001_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2050-7771-2-10","article-title":"Micro-RNAs, new performers in multiple myeloma bone marrow microenvironment","volume":"2","author":"Abdi","year":"2014","journal-title":"Biomark. Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2014.12.001_bib0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","article-title":"PSMB8 encoding the \u03b25i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome","volume":"87","author":"Agarwal","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.drup.2014.12.001_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clml.2014.02.004","article-title":"Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"Ahn","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.drup.2014.12.001_bib0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0030","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/mp300044b","article-title":"Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib","volume":"9","author":"Ao","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2014.12.001_bib0035","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0040","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1073\/pnas.1106015108","article-title":"Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome","volume":"108","author":"Arima","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2014.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2014.12.001_bib0050","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2013.05.011","article-title":"Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"37","author":"Attar","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0055","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1158\/1078-0432.CCR-07-4626","article-title":"Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia","volume":"14","author":"Attar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0060","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","article-title":"Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502","volume":"31","author":"Attar","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0065","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/leu.2011.383","article-title":"The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse","volume":"26","author":"Bachas","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib1040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bcp.2008.11.024","article-title":"Cooperation between Apo2L\/TRAIL and bortezomib in multiple myeloma apoptosis","volume":"77","author":"Balsas","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2014.12.001_bib0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.leukres.2011.09.011","article-title":"Bortezomib resistance in a myeloma cell line is associated to PSM\u03b25 overexpression and polyploidy","volume":"36","author":"Balsas","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4049\/jimmunol.0903182","article-title":"Prevention of experimental colitis by a selective inhibitor of the immunoproteasome","volume":"185","author":"Basler","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2014.12.001_bib0080","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","article-title":"Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"24","author":"Berenson","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00277-008-0501-0","article-title":"Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1\/2 study after longer follow-up","volume":"87","author":"Berenson","year":"2008","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0090","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/leu.2012.51","article-title":"A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Berenson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nsmb.2780","article-title":"New insights into ubiquitin E3 ligase mechanism","volume":"21","author":"Berndsen","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/35014014","article-title":"Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response","volume":"2","author":"Bertolotti","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0105","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/BJ20100383","article-title":"Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit","volume":"430","author":"Blackburn","year":"2010","journal-title":"Biochem. J"},{"key":"10.1016\/j.drup.2014.12.001_bib0115","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","article-title":"Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia","volume":"119","author":"Blum","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/biom4020566","article-title":"PA28\u03b1\u03b2: the enigmatic magic ring of the proteasome?","volume":"4","author":"Cascio","year":"2014","journal-title":"Biomolecules"},{"key":"10.1016\/j.drup.2014.12.001_bib0125","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/emboj\/21.11.2636","article-title":"Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes","volume":"21","author":"Cascio","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.drup.2014.12.001_bib0130","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0135","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","article-title":"Progressively impaired proteasomal capacity during terminal plasma cell differentiation","volume":"25","author":"Cenci","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.drup.2014.12.001_bib0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drup.2014.12.001_bib0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2014.12.001_bib0150","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0155","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0160","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.cellsig.2010.03.003","article-title":"PhosphoMARCKS drives motility of mouse melanoma cells","volume":"22","author":"Chen","year":"2010","journal-title":"Cell. Signal."},{"key":"10.1016\/j.drup.2014.12.001_bib0165","first-page":"1","article-title":"Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors","volume":"8","author":"Cheriyath","year":"2007","journal-title":"Drugs Res. Dev."},{"key":"10.1016\/j.drup.2014.12.001_bib0170","doi-asserted-by":"crossref","first-page":"28026","DOI":"10.1074\/jbc.M301048200","article-title":"Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation","volume":"278","author":"Chondrogianni","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2014.12.001_bib0175","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1074\/jbc.M413007200","article-title":"Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates","volume":"280","author":"Chondrogianni","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2014.12.001_bib0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: from the lysosome to ubiquitin and the proteasome","volume":"6","author":"Ciechanover","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0185","series-title":"Resistance to Proteasome Inhibitors in Cancer","first-page":"181","article-title":"Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies","author":"Cloos","year":"2014"},{"key":"10.1016\/j.drup.2014.12.001_bib0190","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0195","series-title":"Resistance to Proteasome Inhibitors in Cancer","first-page":"47","article-title":"Resistance to proteasome inhibitors in multiple myeloma","author":"Cottini","year":"2014"},{"key":"10.1016\/j.drup.2014.12.001_bib0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1083\/jcb.200510071","article-title":"A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling","volume":"173","author":"Dantuma","year":"2006","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0205","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D\u2019Arcy","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2014.12.001_bib0210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bcp.2011.10.009","article-title":"Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer","volume":"83","author":"De Wilt","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2014.12.001_bib0215","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2014.12.001_bib0225","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01542.x","article-title":"Emerging therapies for the treatment of relapsed or refractory multiple myeloma","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0235","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/1535-7163.MCT-08-1169","article-title":"Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy","volume":"8","author":"Ding","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2014.12.001_bib0240","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2353\/ajpath.2007.070188","article-title":"Linking of autophagy to ubiquitin\u2013proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability","volume":"171","author":"Ding","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drup.2014.12.001_bib0245","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1158\/0008-5472.CAN-10-1883","article-title":"The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer","volume":"71","author":"Fellerhoff","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0250","doi-asserted-by":"crossref","first-page":"e7833","DOI":"10.1371\/journal.pone.0007833","article-title":"A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis","volume":"4","author":"Finlayson","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drup.2014.12.001_bib0255","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2014.12.001_bib0260","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/1529-0131(199803)41:3<560::AID-ART24>3.0.CO;2-P","article-title":"Association of large molecular weight proteasome 7 gene polymorphism with ankylosing spondylitis","volume":"41","author":"Fraile","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.drup.2014.12.001_bib0265","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0270","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcb.21405","article-title":"Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells","volume":"103","author":"Fuchs","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.drup.2014.12.001_bib0275","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0280","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Gallerani","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2014.12.001_bib0285","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib\u2013thalidomide\u2013dexamethasone over the dual combination of thalidomide\u2013dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0290","first-page":"4021","article-title":"Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia","volume":"27","author":"Gil","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0295","article-title":"Genetics of proteasome diseases","volume":"637629","author":"Gomes","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.drup.2014.12.001_bib0300","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.bbagen.2011.01.009","article-title":"Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein?","volume":"1810","author":"Green","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drup.2014.12.001_bib0305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.187.1.97","article-title":"Immunoproteasome assembly: cooperative incorporation of interferon-y (IFNy)-inducible subunits","volume":"187","author":"Griffin","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2014.12.001_bib0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri2687","article-title":"Proteasomes in immune cells: more than peptide producers?","volume":"10","author":"Groettrup","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2014.12.001_bib0315","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.V81.2.490.490","article-title":"P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy","volume":"81","author":"Grogan","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0320","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"10.1016\/j.drup.2014.12.001_bib0325","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bbrc.2012.03.056","article-title":"Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma","volume":"420","author":"Gu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2014.12.001_bib0330","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-8722-4-37","article-title":"Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells","volume":"4","author":"Hao","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0335","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/0008-5472.CAN-05-2872","article-title":"Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency","volume":"66","author":"Heink","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0340","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.0501711102","article-title":"IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response","volume":"102","author":"Heink","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2014.12.001_bib0345","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and drug administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0350","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2014.12.001_bib0355","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.2007.06714.x","article-title":"Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells","volume":"138","author":"Hideshima","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0360","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00726-013-1648-0","article-title":"Positioning of aminopeptidase inhibitors in next generation cancer therapy","volume":"46","author":"Hitzerd","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.drup.2014.12.001_bib0365","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study","volume":"13","author":"Horton","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0370","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/pbc.25117","article-title":"A Phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the children's oncology group","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.drup.2014.12.001_bib0375","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.leukres.2013.09.003","article-title":"A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia","volume":"37","author":"Howard","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0380","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drup.2014.12.001_bib0385","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0390","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0395","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/leu.2013.152","article-title":"Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study","volume":"27","author":"Jakubowiak","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0400","doi-asserted-by":"crossref","first-page":"e32584","DOI":"10.1371\/journal.pone.0032584","article-title":"Blocking autophagy prevents bortezomib-induced NF-\u03baB activation by reducing I-\u03baB\u03b1 degradation in lymphoma cells","volume":"7","author":"Jia","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drup.2014.12.001_bib0405","first-page":"3660","article-title":"Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines","volume":"58","author":"Johnsen","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0410","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/cb2002544","article-title":"Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A","volume":"6","author":"Kale","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0415","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1021\/jm300434z","article-title":"Molecular mechanisms of acquired proteasome inhibitor resistance","volume":"55","author":"Kale","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2014.12.001_bib0420","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2014.12.001_bib0425","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0430","series-title":"American Society of Hematology Annual Meeting Abstract, #2290","article-title":"Interim results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed or refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ","author":"Kaspers","year":"2014"},{"key":"10.1016\/j.drup.2014.12.001_bib0435","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ni.2203","article-title":"Mice completely lacking immunoproteasomes show major changes in antigen presentation","volume":"13","author":"Kincaid","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drup.2014.12.001_bib0440","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/j.seminhematol.2012.04.007","article-title":"Discovery and development of second-generation proteasome inhibitors","volume":"49","author":"Kirk","year":"2012","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0445","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0450","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1172\/JCI58414","article-title":"A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans","volume":"121","author":"Kitamura","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2014.12.001_bib0455","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2003.11.004","article-title":"Proteasome and peptidase function in MHC-class-I-mediated antigen presentation","volume":"16","author":"Kloetzel","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.drup.2014.12.001_bib0460","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tibs.2013.10.004","article-title":"The unique functions of tissue-specific proteasomes","volume":"39","author":"Kniepert","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.drup.2014.12.001_bib0465","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume":"10","author":"Komander","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0470","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"Kortuem","year":"2013","journal-title":"Carfilzomib. Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0475","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.leu.2404414","article-title":"Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells","volume":"21","author":"Kraus","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0480","series-title":"American Society of Hematolgy Annual Meeting Abstract, vol. 120","first-page":"919","article-title":"Inhibition of the CRBN-DDB1-CUL4-ROC1 E3 ubiquitin ligase mediates the anti-proliferative and immunomodulatory properties of lenalidomide","author":"Kr\u00f6nke","year":"2012"},{"key":"10.1016\/j.drup.2014.12.001_bib0485","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKFZ1 and IKFZ3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.drup.2014.12.001_bib0490","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0495","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0500","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2014.12.001_bib0505","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0510","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/1078-0432.CCR-10-1878","article-title":"A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias","volume":"17","author":"Lancet","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0515","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2014.12.001_bib0520","series-title":"American Society of Hematology Annual Meeting Abstract, vol. 122","first-page":"280","article-title":"Proteasome maturation protein (POMP) is associated with proteasome inhibitor resistance in myeloma, and its suppression enhances the activity of bortezomib and carfilzomib","author":"Li","year":"2013"},{"key":"10.1016\/j.drup.2014.12.001_bib0525","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2009.03.077","article-title":"MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells","volume":"383","author":"Li","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2014.12.001_bib0530","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1182\/blood-2012-05-426924","article-title":"Sequence analysis of \u03b2-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone","volume":"120","author":"Lichter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0535","first-page":"1","article-title":"Relationship between the proteasomal system and autophagy","volume":"4","author":"Lilienbaum","year":"2013","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0540","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1","volume":"97","author":"Ling","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2014.12.001_bib0545","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.drup.2014.12.001_bib0550","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0555","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.exphem.2008.04.013","article-title":"Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line","volume":"36","author":"Lu","year":"2008","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0560","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/j.1751-553X.2009.01145.x","article-title":"The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562\/A02","volume":"32","author":"L\u00fc","year":"2010","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0565","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","volume":"37","author":"Lu","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0570","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.108.138131","article-title":"Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma\/leukemia line","volume":"326","author":"Lu","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2014.12.001_bib1045","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","article-title":"Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed multiple myeloma","volume":"123","author":"Ludwig","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0575","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","article-title":"Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells","volume":"6","author":"Markovina","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0580","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nsmb.2792","article-title":"Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways","volume":"21","author":"Mattiroli","year":"2014","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0585","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/era.13.9","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"13","author":"McBride","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.drup.2014.12.001_bib0590","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2014.12.001_bib0595","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/B978-0-12-394387-3.00004-5","article-title":"HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer","volume":"116","author":"McConkey","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0600","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0605","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.drup.2014.12.001_bib0610","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia and lymphoma (TACL) study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0615","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbamcr.2013.05.026","article-title":"RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination","volume":"1843","author":"Metzger","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drup.2014.12.001_bib0620","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1158\/0008-5472.CAN-08-4783","article-title":"Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression","volume":"69","author":"Micallef","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0625","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/0008-5472.CAN-08-2839","article-title":"The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib","volume":"69","author":"Milani","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0630","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0635","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","article-title":"Blockade of XBP1 splicing by inhibition of IRE1\u03b1 is a promising therapeutic option in multiple myeloma","volume":"119","author":"Mimura","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0640","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00280-006-0367-6","article-title":"Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status","volume":"60","author":"Minderman","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2014.12.001_bib0645","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0650","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2014.12.001_bib0655","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrm2630","article-title":"Molecular mechanisms of proteasome assembly","volume":"10","author":"Murata","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0660","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/emboj.2012.354","article-title":"Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?","volume":"32","author":"Nathan","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.drup.2014.12.001_bib0665","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.cell.2013.01.037","article-title":"Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins","volume":"152","author":"Nathan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.drup.2014.12.001_bib0670","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0675","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1586\/era.13.4","article-title":"Proteasome inhibitors in acute leukemia","volume":"13","author":"Niewerth","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.drup.2014.12.001_bib0680","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2014.12.001_bib0685","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.114.092114","article-title":"Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)","volume":"86","author":"Niewerth","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2014.12.001_bib0690","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-7-7","article-title":"Interferon-y-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines","volume":"7","author":"Niewerth","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0695","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2014.02.005","article-title":"Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924","volume":"89","author":"Niewerth","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2014.12.001_bib0700","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00280-013-2136-7","article-title":"The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias","volume":"71","author":"O\u2019Connor","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2014.12.001_bib0705","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0710","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0715","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: lessons from the first decade","volume":"14","author":"Orlowski","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0720","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0725","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0730","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","article-title":"Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0735","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"P\u00e9rez-Gal\u00e1n","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0740","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0745","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0750","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.leukres.2005.06.014","article-title":"No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib","volume":"30","author":"Politou","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0755","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.drup.2014.12.001_bib0760","first-page":"2320","article-title":"Polymorphism in the MHC-encoded LMP7 Gene: association with JRA without Functional Significance for Immunoproteasome Assembly","volume":"28","author":"Prahalad","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.drup.2014.12.001_bib0765","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.bbamcr.2014.05.005","article-title":"Enhanced rate of degradation of basic proteins by 26S immunoproteasomes","volume":"1843","author":"Raule","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drup.2014.12.001_bib0770","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/35085509","article-title":"Plasma cell differentiation requires the transcription factor XBP-1","volume":"412","author":"Reimold","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drup.2014.12.001_bib0775","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1093\/emboj\/16.20.6087","article-title":"Dynamics of proteasome distribution in living cells","volume":"16","author":"Reits","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.drup.2014.12.001_bib0780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1074-7613(02)00511-3","article-title":"Peptide diffusion, protection, anddegradation in nuclear and cytoplasmic compartments before antigen presentationby MHC class I","volume":"18","author":"Reits","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2014.12.001_bib0785","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0790","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.12.001_bib0795","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2014.12.001_bib0800","series-title":"American Society of Hematology Annual Meeting Abstract, vol. 122","first-page":"535","article-title":"Twice-weekly oral MLN9708 (Ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): final phase 1 results and phase 2 data","author":"Richardson","year":"2013"},{"key":"10.1016\/j.drup.2014.12.001_bib0805","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Brief report Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0810","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2014.12.001_bib0815","series-title":"American Society of Hematology Annual Meeting Abstract, vol. 118","first-page":"302","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","author":"Richardson","year":"2011"},{"key":"10.1016\/j.drup.2014.12.001_bib0820","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0825","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2009-09-243402","article-title":"Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia","volume":"115","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(02)80012-8","article-title":"Protein degradation and the generation of MHC class I-presented peptides","volume":"80","author":"Rock","year":"2002","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.drup.2014.12.001_bib1050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/ejh.12325","article-title":"Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed\/refractory myeloma patients","volume":"93","author":"Romano","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0835","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2014.12.001_bib0840","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/leu.2009.8","article-title":"Characterization of the ubiquitin\u2013proteasome system in bortezomib-adapted cells","volume":"23","author":"Ruckrich","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib0845","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2007.07.049","article-title":"Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors","volume":"361","author":"Rumpold","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2014.12.001_bib0850","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0855","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3324\/haematol.2011.051169","article-title":"Can multiple myeloma become a curable disease?","volume":"96","author":"San-Miguel","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2014.12.001_bib0860","first-page":"705714","article-title":"Phase II Study of bortezomib as a single agent in patients with previously untreated or relapsed\/refractory acute myeloid leukemia ineligible for intensive therapy","volume":"2013","author":"Sarlo","year":"2013","journal-title":"Leuk. Res. Treat."},{"key":"10.1016\/j.drup.2014.12.001_bib0865","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2141.2004.05319.x","article-title":"MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia","volume":"128","author":"Schaich","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0870","series-title":"Resistance to Proteasome Inhibitors in Cancer","first-page":"1","article-title":"Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer","author":"Schmitt","year":"2014"},{"key":"10.1016\/j.drup.2014.12.001_bib0875","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/35008096","article-title":"Rapid degradation of a large fraction of newly synthesized proteins by proteasomes","volume":"404","author":"Schubert","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drup.2014.12.001_bib0880","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress","volume":"142","author":"Seifert","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drup.2014.12.001_bib0885","series-title":"American Society of Hematology Annual Meeting Abstract, vol. 122","first-page":"1994","article-title":"Feasibility and activity of bortezomib-based therapy in patients with relapsed\/refractory multiple myeloma previously treated with carfilzomib","author":"Shah","year":"2013"},{"key":"10.1016\/j.drup.2014.12.001_bib0890","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.exphem.2011.09.003","article-title":"Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen","volume":"39","author":"Shuqing","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0895","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0900","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2010.08491.x","article-title":"PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo","volume":"152","author":"Singh","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0905","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","article-title":"Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib","volume":"84","author":"Sood","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0910","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drup.2014.12.001_bib0915","first-page":"4614","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","volume":"113","author":"Sprynski","year":"2009","journal-title":"Lymphoid Neoplasia"},{"key":"10.1016\/j.drup.2014.12.001_bib0920","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev-biophys-051013-022958","article-title":"Structural and functional insights to ubiquitin-like protein conjugation","volume":"43","author":"Streich","year":"2014","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.drup.2014.12.001_bib0925","doi-asserted-by":"crossref","first-page":"e27996","DOI":"10.1371\/journal.pone.0027996","article-title":"Molecular mechanisms of bortezomib resistant adenocarcinoma cells","volume":"6","author":"Suzuki","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drup.2014.12.001_bib0930","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0935","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0940","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cell.2010.08.002","article-title":"The immunoproteasome cleans up after inflammation","volume":"142","author":"van Deventer","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drup.2014.12.001_bib0945","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2162-3619-2-2","article-title":"Overcoming bortezomib resistance in human B cells by anti-CD20\/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors","volume":"2","author":"Verbrugge","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib0950","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drup.2014.12.001_bib0955","first-page":"84","article-title":"Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity","volume":"24","author":"Vigneron","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0960","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","article-title":"Carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib","volume":"158","author":"Vij","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0965","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"Carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0970","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2014.12.001_bib0975","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0980","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0985","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/1078-0432.CCR-07-5150","article-title":"Proteasome B subunit pharmacogenomics: gene resequencing and functional genomics","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib0990","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drup.2014.12.001_bib0995","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","article-title":"The double-edged sword of autophagy modulation in cancer","volume":"15","author":"White","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib1000","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12032-008-9107-6","article-title":"In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies","volume":"26","author":"Wiberg","year":"2009","journal-title":"Med. Oncol."},{"key":"10.1016\/j.drup.2014.12.001_bib1005","doi-asserted-by":"crossref","first-page":"A164","DOI":"10.1186\/1546-0096-11-S1-A164","article-title":"PW02-024 \u2013 a case of candle syndrome treated with thalidomide","volume":"11","author":"Yamazaki","year":"2013","journal-title":"Pediatr. Rheumatol."},{"key":"10.1016\/j.drup.2014.12.001_bib1010","first-page":"1","article-title":"Targeting phospho-MARCKS overcomes drug resistance and induces antitumor activity in preclinical models of Multiple Myeloma","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2014.12.001_bib1015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.it.2006.06.008","article-title":"The DRiP hypothesis decennial: support, controversy, refinement and extension","volume":"27","author":"Yewdell","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drup.2014.12.001_bib1020","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","article-title":"Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy","volume":"18","author":"Zang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2014.12.001_bib1025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature07203","article-title":"From endoplasmic-reticulum stress to the inflammatory response","volume":"454","author":"Zhang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drup.2014.12.001_bib1030","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasomeinhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2014.12.001_bib1035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/onc.2009.343","article-title":"Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells","volume":"29","author":"Zhu","year":"2010","journal-title":"Oncogene"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876461400079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876461400079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T19:51:46Z","timestamp":1717617106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876461400079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":210,"alternative-id":["S136876461400079X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2014.12.001","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2014.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}